JNJ
Johnson & JohnsonHealthcare · $643.9B market cap
Verdict
Share price
$256.03
close of Oct 3, 2026
Fair value
$172.87
Sticker Price
Payback Price
$69.15
buy price
JNJ is Overpriced: at $256.03 it trades 48% above its fair value of $172.87. Its buy price (Payback Price) is $69.15, 73% below today's price. Business quality is limited: only 1 of 5 key numbers clears the 10% bar.
How we valued it
Owner Earnings. Earnings grow slowly (under 7% a year), but cash flow is steady, so we value it on its cash flow instead of its earnings.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow JNJ
Get notified when it reaches its buy price of $69.15. Free.
Create a free accountSuperinvestors
12 of the investors we track hold JNJ. In Q2 2026, 1 opened a position, 3 trimmed and 1 sold out. Who we track
Yacktman Asset Management
Yacktman Asset Management · as of Q2 2026
$320.0M
1,259,977 shares
Thomas Gayner
Markel Group · as of Q2 2026
$155.1M
610,800 shares
Mairs & Power Funds
Mairs & Power Funds · as of Q2 2026
$107.4M
423,010 shares
Tweedy Browne
Tweedy Browne · as of Q2 2026
$51.2M
201,644 shares
Prem Watsa
Fairfax Financial Holdings · as of Q2 2026
$18.6M
73,400 shares
Show all 12 holdersShow fewer
John Rogers
Ariel Investments · as of Q2 2026
$9.0M
35,393 shares
Dodge & Cox Funds
Dodge & Cox Funds · as of Q2 2026
$5.3M
20,947 shares
Jensen Investment Management
Jensen Investment Management · as of Q2 2026
$2.2M
8,797 shares
Torray Funds
Torray Funds · as of Q2 2026
$1.1M
4,141 shares
David Katz
Matrix Asset Advisors · as of Q2 2026
$412K
1,622 shares
Thomas Russo
Gardner Russo & Quinn · as of Q2 2026
$282K
1,112 shares
Christopher Bloomstran
Semper Augustus · as of Q2 2026
$202K
794 shares
Moves in Q2 2026
New position: Christopher Bloomstran
Trimmed: Thomas Russo, Mairs & Power Funds, John Rogers
Sold out: Richard Pzena
Insider activity
Since Jul 20, 2026: no open-market purchases, 9 sales worth $64.7M and 10 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
Schmid Timothy
EVP, WW Chair, MedTech · 2026-09-02
Sold
$6.2M
Taubert Jennifer L
EVP, WWC. Innovative Medicine · 2026-08-17
Sold
$4.0M
Duato Joaquin
CEO and Chairman of the Board · 2026-08-13
Sold
$26.7M
Duato Joaquin
CEO and Chairman of the Board · 2026-08-13
Sold
$5.5M
Forminard Elizabeth
EVP, Chief Legal Officer · 2026-08-06
Sold
$1.7M
Other filings
HEWSON MARILLYN A
director · 2026-09-08
Award
180.956 shares
Woods Eugene A.
director · 2026-09-08
Award
135.717 shares
Pinto Daniel E
director · 2026-09-08
Award
113.098 shares
Schmid Timothy
EVP, WW Chair, MedTech · 2026-09-02
Option exercise
$3.4M
Schmid Timothy
EVP, WW Chair, MedTech · 2026-09-02
Option exercise
$1.5M
Show all 10 other filingsShow fewer
Taubert Jennifer L
EVP, WWC. Innovative Medicine · 2026-08-17
Option exercise
$1.7M
Duato Joaquin
CEO and Chairman of the Board · 2026-08-13
Option exercise
$14.3M
Forminard Elizabeth
EVP, Chief Legal Officer · 2026-08-06
Option exercise
$1.2M
Broadhurst Vanessa
EVP, Global Corp Affairs · 2026-07-20
Option exercise
$1.4M
Broadhurst Vanessa
EVP, Global Corp Affairs · 2026-07-20
Option exercise
$1.6M
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of…
Drug Manufacturers - General
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works